Pande: Genomic diagnostics scale across cancer types via repeatable engineering
Vijay Pande · a16z Podcast | Taking the Pulse on Bio · Jan 2, 2019 · at 7:12
Vijay Pande, General Partner at Andreessen Horowitz, contrasts traditional disease-specific biological discovery with scalable, data-driven genomic diagnostic engineering.
0:00 / 0:22exact quote · 22.3s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“Science is something that you can't schedule creativity or the ability to come through a breakthrough. So if you have understood the science of colorectal cancer, what you've learned about a stool test probably is not going to be very useful for a breast cancer test. It'd be a completely different biology. But if you're using genomics and you can be able to learn from training from samples, it's basically just getting new data and new samples and repeating the exact same process.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Vijay Pande
Pande: Cancer could easily not exist in 10 years
“Cancer could easily just not exist in 10 years, and that's due to this change in how we think about things, and there's all these things on the back end.”
Vijay Pande: Compute costs will fall a million-fold over 20 years
“The nice thing about the exponentials is that, you know, things will go down a factor of a thousand, like, every 10 years on the Moore's Law side, and we'll continue to see that. So, a thousand, maybe in 20 years, a million, you know, a thousand times a thousa…”
Pande: Healthcare AI needs a 10x improvement threshold to overcome stigma
“Yeah, so I think the bar is different. This might be the magic has to get to 10 X. Mm-hmm. Something where 10% is probably within noise and without doubt or something like that, but 10 X is kind of the thing where, like, okay, okay. We have to think of things …”
Pande: Healthcare service providers will eventually transition into AI companies
“Well, you can imagine a services company that's providing some sort of healthcare service. It's training AI with its workers. And then the easy things, which are probably the boring things anyways, AI starts to do. And then the more interesting, complicated th…”
Pande: FDA rejects new drugs that are cheaper but equal in efficacy
“If you had a drug that was as good as the best drug, but cheaper, That still can't get that won't go by the FDA because they actually has to be better than the last drug, even if it's not better scientifically, but it's better in other ways.”